Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 8/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13925522 | 1.00 | APP (0.61) | APPALDH1A1LMNAMAPTHPGD | |
| SCHEMBL13925526 | 0.89 | LMNA (0.58) | APPALDH1A1LMNAMAPTHPGD | |
| SCHEMBL22537507 | 0.88 | APP (0.66) | APPALDH1A1LMNAMAPTHPGD | |
| SCHEMBL5929490 | 0.86 | MAPT (0.62) | ALDH1A1LMNAMAPTHPGDSMN1; SMN2 | |
| SCHEMBL17445912 | 0.84 | ALDH1A1 (0.66) | ALDH1A1LMNAMAPTHPGDSMN1; SMN2 | |
| SCHEMBL2628197 | 0.83 | APP (0.58) | APPALDH1A1LMNASMN1; SMN2HRH3 | |
| SCHEMBL19113684 | 0.83 | APP (0.58) | APPALDH1A1LMNASMN1; SMN2HRH3 | |
| SCHEMBL10457449 | 0.83 | APP (0.59) | APPALDH1A1KCNH2 | |
| SCHEMBL16063140 | 0.83 | LTA4H (0.60) | ALDH1A1LMNAMAPTHPGDSMN1; SMN2 | |
| SCHEMBL301362 | 0.83 | NR1I2 (0.60) | ALDH1A1LMNAMAPTHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017049080-A1 | ANTIFUNGAL COMPOUND PROCESS | VIAMET PHARMACEUTICALS, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2015143142-A1 | ANTIFUNGAL COMPOUND PROCESS | VIAMET PHARMACEUTICALS, INC. (US) | 2015-09-24 | — | — | WO | disclosed |
| WO-2012150220-A1 | RADIOLABELED AMINO ACIDS FOR DIAGNOSTIC IMAGING | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-11-08 | — | — | WO | disclosed |
| US-20090312318-A1 | THERAPEUTIC COMPOUNDS AND METHODS | GILEAD SCIENCES, INC. | 2009-12-17 | — | — | US | disclosed |
| US-20080070910-A1 | Therapeutic compounds and methods | GILEAD SCIENCES, INC. | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312318-A1 | THERAPEUTIC COMPOUNDS AND METHODS | SERPINB1, ABCC1, SERPINB6 | APP 613/4885ALDH1A1 1840/4885LMNA 741/4885 |
| US-20080070910-A1 | Therapeutic compounds and methods | SERPINB1, ABCC1, SERPINB6 | APP 613/4885ALDH1A1 1840/4885LMNA 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.